hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06371638, orgStudyIdInfo id: 2024-01, briefTitle: Dexmedetomidine and Postoperative Cognitive Dysfunction (POCD), acronym: CODE-POCD, statusModule overallStatus: COMPLETED, startDateStruct date: 2024-01-07, primaryCompletionDateStruct date: 2024-03-01, completionDateStruct date: 2024-03-07, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Udayana University, class: OTHER, descriptionModule briefSummary: Postoperative cognitive dysfunction (POCD) affects all age groups and can lead to increased morbidity and more extended hospital stays. Dexmedetomidine reduces POCD by inhibiting the increase in proinflammatory cytokines IL-6 and TNF-α, and its anti-inflammatory activity contributes to its protective effect. Previous studies found that dexmedetomidine reduced POCD incidence in non-cardiac and cardiac surgery. Therefore, the goal of this study was to specifically investigate if using TCI dexmedetomidine to maintain anaesthesia in laparotomy surgeries reduces the incidence of POCD compared to inhalation anaesthesia by sevoflurane., conditionsModule conditions: Postoperative Cognitive Dysfunction, conditions: Postoperative Pain, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 112, type: ACTUAL, armsInterventionsModule interventions name: Dexmedetomidine, interventions name: Sevoflurane, outcomesModule primaryOutcomes measure: Postoperative cognitive dysfunction (POCD), primaryOutcomes measure: Postoperative cognitive dysfunction (POCD), secondaryOutcomes measure: Intraoperative hemodynamics: mean arterial pressure (MAP), secondaryOutcomes measure: Intraoperative hemodynamics: heart rate (HR), secondaryOutcomes measure: Postoperative pain, secondaryOutcomes measure: Postoperative pain, secondaryOutcomes measure: Postoperative pain, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Prof. Ngoerah General Hospital, city: Denpasar, state: Bali, zip: 80114, country: Indonesia, geoPoint lat: -8.65, lon: 115.21667, hasResults: False
protocolSection identificationModule nctId: NCT06371599, orgStudyIdInfo id: MersinU*GUGUCU_003, briefTitle: The Effect of Watching Cartoons and Playing Games as Distraction Method During Peripheral Intravenous Cannula Placement on Pain and Fear in Children Aged 6-9 Years, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-11-20, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Mersin University, class: OTHER, descriptionModule briefSummary: Active and passive distraction methods are frequently used in the nursing management of procedural pain in children. There are no studies comparing the effects of watching cartoon (passive) and playing game (active) as distraction methods on pain and fear associated with peripheral intravenous cannula placement in children aged 6-9 years.This study aimed to compare the effects of playing game (active distraction) and watching cartoon (passive distraction) techniques on pain and fear during peripheral intravenous cannula placement in children aged 6-9 years., conditionsModule conditions: Procedural Pain, conditions: Fear of Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: DOUBLE, maskingDescription: The children and their parents will be blinded to the groups. The principal researchers (R1, R2) will be blinded to the research hypotheses. The opaque envelopes are stored in a locked cabinet by the researcher who performed the randomization. Data entries will be performed using the codes A and B. Codes will be shared with the researchers after statistical analyses are conducted and the research report is written., whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 64, type: ESTIMATED, armsInterventionsModule interventions name: Playing game, interventions name: Watching cartoon, outcomesModule primaryOutcomes measure: Pain assesed by Wong-Baker FACES, primaryOutcomes measure: Fear by Children's Fear Scale, secondaryOutcomes measure: Pain assesed by Wong-Baker FACES, secondaryOutcomes measure: Fear by Children's Fear Scale, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 9 Years, stdAges: CHILD, contactsLocationsModule locations facility: Mersin University, city: Mersin, state: Yenişehir, zip: 33343, country: Turkey, geoPoint lat: 36.79526, lon: 34.61792, hasResults: False
protocolSection identificationModule nctId: NCT06371586, orgStudyIdInfo id: NCC4537, briefTitle: Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2027-03-01, completionDateStruct date: 2027-03-01, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences, class: OTHER, descriptionModule briefSummary: The regimen of Albumin paclitaxel+SOX+BEV neoadjuvant therapy lasted for 6 cycles, during which PD-1 monoclonal antibody therapy was interspersed for 4 cycles for locally advanced diffuse gastric cancer., conditionsModule conditions: Gastric Cancer, conditions: Diffuse Type Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 67, type: ESTIMATED, armsInterventionsModule interventions name: Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy, outcomesModule primaryOutcomes measure: Pathological response rate, secondaryOutcomes measure: EFS, secondaryOutcomes measure: OS, secondaryOutcomes measure: R0, secondaryOutcomes measure: Safety (adverse events) and surgical complications, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cancer hospital，Chinese acadamy of medical sciences, status: RECRUITING, city: Beijing, country: China, contacts name: Chunxia Du, role: CONTACT, phone: 87787121, email: retinadcx@vip.163.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06371560, orgStudyIdInfo id: KAP-ABR-Perio, briefTitle: Antibiotics, Antibiotic Resistance, and Prescribing Practices Among Periodontists: Cross Sectional KAP Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-25, primaryCompletionDateStruct date: 2024-09-30, completionDateStruct date: 2024-10-30, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: Antibiotic resistance is a global health threats that require attention from all healthcare providers. In Periodontology, antibiotic is prescribed in many clinical situations. The aim of this study is to assess the followings among Periodontists (1) The knowledge, attitude, and practices (KAP) towards antibiotics and antibiotic resistance; (2) The prescribing practices of antibiotics in periodontal therapy; (3) The correlation between personal perception of antibiotics uses and the professional prescription patterns; and (4) The differences in antibiotics prescription in relation to the years of experience and the academic background., conditionsModule conditions: Antibiotic Resistance, conditions: Antibiotic Use, conditions: Periodontitis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 400, type: ESTIMATED, armsInterventionsModule interventions name: Questionnaire, outcomesModule primaryOutcomes measure: KAP, secondaryOutcomes measure: The prescribing practices of antibiotics in periodontal therapy, secondaryOutcomes measure: The correlation between personal perception of antibiotics uses and the professional prescription patterns, secondaryOutcomes measure: The differences in antibiotics prescription in relation to the years of experience and the academic background., eligibilityModule sex: ALL, minimumAge: 25 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06371547, orgStudyIdInfo id: BEUFTR-3, briefTitle: Efficiency of Different Gastrocnemius Stretching Exercises, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-15, primaryCompletionDateStruct date: 2024-10-15, completionDateStruct date: 2024-12-15, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Bitlis Eren University, class: OTHER, descriptionModule briefSummary: The primary aim of this study is to investigate the effects of different types and durations of gastrocnemius stretching on the viscoelastic properties of the gastrocnemius muscle, Achilles tendon, and plantar fascia.In addition, pain threshold of the gastrocnemius muscle and plantar fascia, as well as on hamstring tightness will be measured., conditionsModule conditions: Muscle Tightness, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: Interventions and assessment will be performed by separate researchers., whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: Stretching Exercise, outcomesModule primaryOutcomes measure: Measurement of the Viscoelastic Properties, primaryOutcomes measure: Ankle-foot Dorsiflexion Index, secondaryOutcomes measure: Measurement of the Mechanosensitivity, secondaryOutcomes measure: Assessment of Hamstring Tightness, otherOutcomes measure: Dominant Leg Determination, otherOutcomes measure: Navicular Drop Test, otherOutcomes measure: Self-reported Effects of Stretching Exercises, otherOutcomes measure: The Satisfaction Level with the Stretching, otherOutcomes measure: Compliance with Stretching Exercise Program, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 25 Years, stdAges: ADULT, contactsLocationsModule locations facility: Bitlis Eren University, city: Bitlis, state: Merkez, zip: 13000, country: Turkey, geoPoint lat: 38.40115, lon: 42.10784, hasResults: False
protocolSection identificationModule nctId: NCT06371534, orgStudyIdInfo id: QL2109-101, briefTitle: A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Qilu Pharmaceutical Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The goal of this clinical trial is to compare the pharmacokinetic and safety similarity of QL2109 with DARZALEX FASPRO® in healthy male volunteers.Participants will receive a single injection of QL2109/ DARZALEX FASPRO® Researchers will compare pharmacokinetic, safety, and immunogenic similarities between the two groups., conditionsModule conditions: Tumor, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 228, type: ESTIMATED, armsInterventionsModule interventions name: QL2109, interventions name: DARZALEX FASPRO®, outcomesModule primaryOutcomes measure: AUC0-∞, primaryOutcomes measure: Cmax, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Zhejiang University School of Medicine, city: Hangzhou, state: Zhejiang, zip: 310006, country: China, contacts name: qingwei zhao, Professor, role: CONTACT, email: qwzhao@zju.edu.cn, contacts name: qingwei zhao, Professor, role: PRINCIPAL_INVESTIGATOR, contacts name: xingjiang hu, Professor, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.29365, lon: 120.16142, locations facility: The First Affiliated Hospital of Zhejiang University School of Medicine, city: Hangzhou, state: Zhejiang, zip: 310006, country: China, contacts name: qingwei ZHAO, Professor, role: CONTACT, email: qwzhao@zju.edu.cn, contacts name: xingjiang HU, Professor, role: CONTACT, email: hxj319@163.com, contacts name: qingwei ZHAO, Professor, role: PRINCIPAL_INVESTIGATOR, contacts name: xingjiang HU, Professor, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06371521, orgStudyIdInfo id: 4933, briefTitle: Ergogenic Effects of Sportlegs, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-24, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Christopher Bell, class: OTHER, descriptionModule briefSummary: Sportlegs is a commercially available dietary/sports supplement. It is manufactured by a local, Colorado-based company: Sport Specifics Inc. Although Sportlegs has been on the market for approximately 20-years, very little empirical research has been completed to determine if Sportlegs improves exercise performance. Sport Specifics Inc. has commissioned Colorado State University to investigate the ergogenic effects of Sportlegs., conditionsModule conditions: Performance Enhancing Product Use, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: Randomized, Placebo-Controlled, Double Blind Crossover Intervention, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: TRIPLE, maskingDescription: Investigators and Participants are both blinded to whether the participants will be consuming Sportlegs or Placebo during a given study visit., whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: Sportlegs, interventions name: Placebo, outcomesModule primaryOutcomes measure: Maximal Oxygen Uptake, primaryOutcomes measure: Lactate Threshold, primaryOutcomes measure: Rating of Perceived Exertion (RPE), primaryOutcomes measure: Maximal sustained mean power, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule locations facility: Colorado State University, status: RECRUITING, city: Fort Collins, state: Colorado, zip: 80523, country: United States, contacts name: Christopher Bell, Ph.D., role: CONTACT, phone: 970-491-7522, email: christopher.bell@colostate.edu, contacts name: Taylor R Ewell, MS, role: CONTACT, phone: 7197611417, email: taylor.ewell@colostate.edu, geoPoint lat: 40.58526, lon: -105.08442, hasResults: False
protocolSection identificationModule nctId: NCT06371495, orgStudyIdInfo id: statins in ischemic stroke, briefTitle: Statins Role in Acute Ischemic Stroke, acronym: observation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-13, primaryCompletionDateStruct date: 2025-02-28, completionDateStruct date: 2025-08-30, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Strokes is amajor cause of death and disabilities in different countried, conditionsModule conditions: Stroke, Acute, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 105, type: ESTIMATED, armsInterventionsModule interventions name: rosuvastatin, outcomesModule primaryOutcomes measure: Carotid duplex will be done at the onset and after 1 month and 3 months of the onset., eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06371482, orgStudyIdInfo id: Camel-01, briefTitle: Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01), statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Hebei Medical University Fourth Hospital, class: OTHER, descriptionModule briefSummary: This trial aims to assess efficacy and safety of durvalumab combined with chemoradiotherapy for limited stage small cell lung cancer., conditionsModule conditions: SCLC, Limited Stage, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 58, type: ESTIMATED, armsInterventionsModule interventions name: Durvalumab, interventions name: Chemotherapy drug of EP regimen, interventions name: radiotherapy, outcomesModule primaryOutcomes measure: Assessment of objective remission rate (ORR) in limited stage small cell lung cancer treated with durvalumab combined with chemoradiotherapy, primaryOutcomes measure: Assessment of the incidence of treatment-related adverse events Incidence of Treatment-Emergent Adverse Events., secondaryOutcomes measure: Assessment of overall survival (OS) in limited stage small cell lung cancer., secondaryOutcomes measure: Assessment of progression-free survival (PFS) in limited stage small cell lung cancer., secondaryOutcomes measure: Assessment of disease control rate (DCR) in limited stage small cell lung cancer., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fourth Hospital of Hebei Medical University, status: RECRUITING, city: Shijiazhuang, state: Hebei, zip: 050011, country: China, contacts name: Wenbin Shen, PhD, role: CONTACT, phone: +86 15831183879, email: wbshen1979@sina.com, contacts name: Hesong Wang, PhD, role: CONTACT, phone: +86 18810775196, email: wanghesongmz@163.com, geoPoint lat: 38.04139, lon: 114.47861, hasResults: False
protocolSection identificationModule nctId: NCT06371469, orgStudyIdInfo id: KAEK-769, briefTitle: Program of Health Behaviour Against to Cancer (PHeBAC), acronym: PHeBAC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-20, primaryCompletionDateStruct date: 2024-07-20, completionDateStruct date: 2024-08-20, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Akdeniz University, class: OTHER, descriptionModule briefSummary: The European Code Against Cancer contains 12 recommendations to reduce the risk of cancer. It is estimated that about half of all cancers could be prevented if all recommendations are followed.The aim of this study was to evaluate the effectiveness of the Program of Health Behaviour Against Cancer (PHeBAC) applied to mothers of children with intellectual disabilities in increasing the participation of mothers and their children with intellectual disabilities in cancer screenings and their health behaviors against cancer. The goal is to improve the preventive health behaviors of children with intellectual disabilities and their mothers against cancer and to increase the rate of participation in cancer screenings. Specific targets are; not smoking and not being exposed to smoking, increasing physical activity, healthy nutrition, limiting alcohol consumption, protection from sunlight, HPV vaccination and increasing participation in breast, cervical and colorectal cancer screenings., conditionsModule conditions: Cancer Prevention, conditions: Health Behavior, conditions: Disability, Intellectual, conditions: Parents, conditions: Cancer Screening, conditions: Experimental Study Designs, conditions: Mothers, conditions: Disabilities Mental, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, maskingDescription: Mothers participating in the research will not know that they are in the intervention or control group. The data of the research will be collected by an independent investigator. In addition telephone support during the research process will be provided by the independent investigator, too, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: PHeBAC, interventions name: Control Group, outcomesModule primaryOutcomes measure: Health Behaviors and Participation in Cancer Screenings Data Collection Form, primaryOutcomes measure: Healthy Life Style Behaviors Scale II (Physical Activity and Nutrition Sub-Factors), primaryOutcomes measure: Sun Protection Behavior Scale, eligibilityModule sex: FEMALE, minimumAge: 30 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False